← Back to Search

Other

Suvorexant for Opioid Use Disorder

Phase < 1
Recruiting
Led By Justin Strickland, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up upon completion of experimental session (~8 hours post drug administration)

Summary

This trial studies if a drug may reduce cravings & pleasure from other drugs, helping people reduce their use.

Who is the study for?
This trial is for adults aged 18-65 with moderate to severe Opioid Use Disorder, as defined by the DSM-5. Participants must have a history of substance use (details blinded), be in good health overall, and pass medical screenings including urine and blood tests. Those seeking opioid treatment, pregnant or breastfeeding individuals, or those with significant mental/physical disorders that could affect participation are excluded.
What is being tested?
The study aims to see if suvorexant (20mg/day) can reduce usage, enjoyment, and craving for opioids compared to other undisclosed drugs (Drug A-D) and a placebo. The effectiveness of suvorexant against these blinded drugs will help understand its potential as a treatment option.
What are the potential side effects?
Suvorexant may cause drowsiness, headache, dizziness, dry mouth or abnormal dreams. Since other drugs are blinded in this study, their specific side effects aren't disclosed but generally could include typical drug reactions like nausea or allergic responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to two weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to two weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cross-Price Elasticity
Demand Elasticity
Demand Intensity
Secondary study objectives
Total Mean Sleep Time

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Suvorexant (20mg/day)Experimental Treatment5 Interventions
Double blind administration of suvorexant once per day during residential stay until discharge
Group II: PlaceboPlacebo Group5 Interventions
Double blind administration of placebo once per day during residential stay until discharge

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,605 Previous Clinical Trials
3,329,843 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,339 Previous Clinical Trials
14,881,711 Total Patients Enrolled
Justin Strickland, PhDPrincipal InvestigatorJohns Hopkins University

Media Library

Suvorexant (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05829655 — Phase < 1
~50 spots leftby Oct 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top